MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...
I rated this company with two stars, and the only reason there are two stars is that the people I have talked to are very nice. The company's policies are outrageous. I was very sick, and my ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback